Senseonics takes over U.S. sales from Ascensia; Q1 revenue up 24% but loss doubles to $32M

Filed May 7, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 8, 2025 · ~2 min read

Key Changes

• high

  Company assumed full U.S. commercialization of Eversense from Ascensia effective January 2026, ending exclusive distribution partnership. European rights became non-exclusive with company retaining 100% of revenue.

  MD&A: Commercialization transition verify on EDGAR →
• high

  Net loss widened to $32.3M in Q1 2026 from $14.3M prior year as SG&A expenses nearly quadrupled to $30.2M, driven by $18M in new selling/marketing costs (headcount expansion, direct-to-consumer campaigns) and $4.5M in transition-related G&A.

  MD&A: Operating expenses verify on EDGAR →
• high

  Management concluded going concern doubt has been alleviated following May 2026 equity offering that raised $86M net and May amendment to Hercules credit facility increasing total capacity to $140M (up from $100M).

  MD&A: Going concern & liquidity verify on EDGAR →